Objective: To assess the reliability and validity of six patient-reported outcomes (PRO) instruments for evaluating health-related quality of life in adults with mild-severe hemophilia B and caregivers of children with hemophilia B, including affected women/girls. . Construct validity and item-total correlation were assessed using Pearson product-moment correlation, internal consistency was assessed using Cronbach's alpha coefficient, and known-group validity was assessed by comparisons to self-reported characteristics based on the Kruskal-Wallis test.
| INTRODUC TI ON
Hemophilia is a congenital bleeding disorder that frequently results in arthropathy caused by repeated joint bleeds. 1, 2 Advances in hemophilia treatment during the past four decades have increased life expectancies for people with hemophilia (PWH), leading to a greater prevalence of health issues related to hemophilia and aging, including arthropathy and its complications. 3, 4 Hemophilic arthropathy often leads to acute and/or chronic pain and mobility impairment, potentially affecting health-related quality of life (HRQoL) for PWH. 5, 6 Hemophilia is an X-linked disorder resulting from a deficiency in coagulation factor VIII (hemophilia A) or factor IX (hemophilia B) and predominantly affects boys and men, but girls and women who are carriers of hemophilia mutations may also be affected by bleeding. A minority of female carriers have factor levels corresponding to mild, moderate, or severe hemophilia due to lyonization (skewed X chromosome inactivation). 7 One of the largest studies focusing on HRQoL in PWH was the Hemophilia Experiences, Results, and Opportunities (HERO) study, which included 675 adults with hemophilia A or B and 561 parents of children with hemophilia from 10 different countries. 8 The study population of HERO was predominantly those with hemophilia A (74%). Although this proportion is reflective of the prevalence of hemophilia A vs B in the overall hemophilia population, 9 individuals with hemophilia B, those with mild and moderate hemophilia, and women and girls were underrepresented in the HERO study population, 8 and studies focusing on HRQoL in people with hemophilia B specifically are limited. To address this shortcoming, the Bridging Hemophilia B Experiences, Results, and Opportunities into Solutions (B-HERO-S) study was developed to evaluate the impact of hemophilia on psychosocial issues and HRQoL for men and women with hemophilia B and caregivers of children with hemophilia B. The aim of this paper is to describe the reliability (internal consistency and item-total correlation) and validity (construct and known-group) of patient-reported outcome (PRO) instruments administered to participants in the B-HERO-S study.
| ME THODS

| Study design
The methodology of B-HERO-S has been described previously. 10 Briefly, adults with hemophilia B (aged ≥18 years) and caregivers of children with hemophilia B (aged <18 years) in the United
States were recruited with an institutional review board-approved information letter through email and social media outreach by three patient advocacy organizations (Coalition for 
| PRO instruments
Surveys included several generic and hemophilia-specific PRO instruments administered to adults with hemophilia (EQ-5D-5L, Brief scale).
The EQ-5D-5L is a generic utility measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression, as well as patient-rated overall health. The BPI is a generic measure of bodily pain severity and interference over the previous 7 days, with higher scores indicating greater pain severity or interference. Pain severity and pain interference domain scores were calculated by averaging the ratings of the items con- and GAD-7 ask respondents to report on their symptoms in the previous 2 weeks.
| Statistical analysis
Patient-reported outcomes instrument scores were calculated according to standard protocols. 11, [13] [14] [15] [16] [17] Data were managed and processed by Huron Consulting Services with direction from Novo
Nordisk Inc Statistical analyses were performed by AMF Consulting.
Internal consistency of PRO global and domain scores were measured using Cronbach's alpha coefficient (α > 0.70 was considered satisfactory). 18, 19 Item-total correlation, which measures correlation between individual items and the total score, omitting the item being assessed, was measured by Pearson product-moment correlation (r > 0.20 was considered satisfactory). 20 Construct validity was assessed using Pearson product-moment correlation (r > 0.37 was considered satisfactory). 21 Known-group validity was assessed by comparisons to predefined self-reported demographic, disease, and treatment-related characteristics based on the Kruskal-Wallis test (P values). Bleeding patterns in adult men and women responding as adults with hemophilia were similar, with predominantly joint and muscle bleeding, and differed from patterns in mothers responding as caregivers who identified themselves as symptomatic carriers.
| RE SULTS
| Participant characteristics
| Internal consistency
All PRO domain scores for both adults with hemophilia and caregivers of children with hemophilia had Cronbach's alpha above the threshold of 0.70 18, 19 with values ranging from 0.74 to 0.97, except
for HAL self-care (α = 0.43; Table 1 ). Internal consistency was particularly high for adult participants on BPI pain interference and pain severity, PHQ-9, and several item and domain scores in HAL (legs, household tasks, leisure activities, UE activities, BLE activities, and CLE activities), and for caregiver reports of GAD-7, each of which had α > 0.90.
| Item-total correlation
In PRO instruments administered to adults with hemophilia B,
Pearson correlation was within the acceptable parameter of r > 0.20 20 for all five EQ-5D-5L items, four BPI pain severity items, seven BPI pain interference items, all HAL scores, three IPAQ items, and all PHQ-9 items (Table 2a- 
| Construct validity
In the assessment of construct validity for PRO instruments administered in adults with hemophilia B, nearly all correlations showed satisfactory validity (r > 0.37), and nearly all reached significance (P < 0.01) and showed expected directionality ( Table 3 Similarly, EQ-5D-5L anxiety/depression was most highly correlated with BPI pain interference (r = 0.73), pain severity (r = 0.72), and PHQ-9 (r = 0.66). EQ-5D-5L index strongly correlated with all PRO scores except PHQ-9 and HAL CLE, and EQ-5D-5L visual analog 
TA B L E 2 (Continued)
scale (VAS) was strongly correlated with all measured scores except PHQ-9, HAL BLE, and HAL CLE. Apart from the EQ-5D-5L correlations already described, BPI pain interference was also strongly correlated with PHQ-9 (r = 0.66) and HAL overall score (r = −0.60, correlation is negative due to the directionality of the BPI scale in which 10 is worst pain interference or severity), and PHQ-9 was highly correlated with BPI pain severity (r = 0.60). For caregivers, construct validity was high between PHQ-9 and GAD-7 (r = 0.92; P < 0.001).
| Known-group validity
All EQ-5D-5L items, index, and VAS scores, as well as both BPI pain interference and pain severity domain scores, showed statistically significant differences among nearly all self-reported characteristics in adults with hemophilia (Table 4) . No significant differences were found in most HAL domain/overall scores across age or self-reported pain groups; additionally, HAL CLE activities scores were not significantly different across anxiety or percentage of life on prophylaxis groups. IPAQ scores demonstrated a lack of significant differences across several known groups, including those defined by depression, hemophilia severity, functional status, and hemophilia treatment.
Caregiver PHQ-9 and GAD-7 scores each showed statistically significant differences across all known groups except for caregiver age (Table 5 ).
| D ISCUSS I ON
The B-HERO-S study provides important insights into psychosocial issues and HRQoL in people with hemophilia B and their caregivers. Previous reports from B-HERO-S described the effect of hemophilia on employment, education, and participation in recreational activities in this population. 10, 22, 23 Overall, PRO results have been reported elsewhere, 24 whereas the analysis presented here aimed to assess reliability and validity of these PROs in symptomatic individuals across hemophilia B severities and including both genders through online administration of PRO instruments. This builds on the findings of the Pain, Functional Impairment and Quality of Life (P-FiQ) study, which confirmed the reliability and validity of a largely overlapping group of PROs in PWH with a history of joint pain or bleeding, supporting the use of these tools to assess hemophilia-related pain and HRQoL in the clinical setting. [25] [26] [27] [28] We assessed reliability using measures of internal consistency and item-total correlation. Internal consistency, a common statistical measure for the correlation between different items within a domain, was satisfactory for all total scores and domains tested except for HAL self-care, suggesting that the less impacted self-care ability may not be an accurate indication of overall functional status. While for nearly all component scores in caregivers. These findings demonstrate the reliability of using these tools to assess quality of life and pain in people with hemophilia B across severities and genders.
The PRO instruments administered in B-HERO-S generally showed high construct validity with anticipated directionality. As expected, scores measuring similar aspects of HRQoL were highly correlated despite differences in the time assessment periods.
For example, PHQ-9 measuring depressive symptoms in the last 2 weeks was highly correlated with EQ-5D-5L anxiety/depression assessed "today," and both BPI pain interference and pain severity assessed over the last week correlated with EQ-5D-5L pain/discomfort "today." While EQ-5D-5L anxiety/depression was moderately correlated with HAL scores, PHQ-9 scores were weakly correlated with HAL scores. Though both of these instruments evaluate aspects of mental health, EQ-5D-5L and PHQ-9 differ in time scale
and PHQ-9 evaluates depression based on the DSM-V diagnostic criteria for depression, whereas EQ-5D-5L asks participants to rate the severity of their problems with anxiety/depression (none, slight, moderate, severe, extreme). Thus differences between their respective correlations with HAL overall score may be a result of fundamental differences between the instruments, and we do not consider an indication of contradictory validity. Both the EQ-5D-5L
index and the VAS were highly correlated with BPI pain severity and interference, as well as with HAL overall score capturing function in the last 4 weeks, suggesting that pain and functional impairment may be drivers of overall HRQoL in people with hemophilia.
Interestingly, several correlations between PRO domains related to pain and anxiety/depression were observed. EQ-5D-5L anxiety/depression was highly correlated with BPI pain interference and pain severity, and PHQ-9 was strongly correlated with BPI pain severity.
These correlations suggest a strong relationship between pain and mental health in individuals with hemophilia, similar to those in the general population. 29 Nearly all PRO instruments discriminated between known groups, with strong correlations between PRO instrument scores and related patient characteristics. EQ-5D-5L pain/discomfort, and both BPI pain interference and pain severity, showed significant differences between self-reported pain groups (yes/no). PHQ-9 and EQ-5D-5L anxiety/depression discriminated between self-reported anxiety and self-reported depression groups. Of note, HAL overall and domain scores did not show significant differences between age groups (<30, 30-45, >45 years), perhaps suggesting that in this study population with potential bias toward more symptomatic patients participating, age is not independently associated with functional impairment.
HAL CLE score showed significant differences in the self-reported pain (yes/no) groups, which may be driven by the prevalence of knee problems in this study population, as 60% of B-HERO-S respondents with specific joint problems reported that the knee joint suffered from bleeds most often. 10 Caregiver PHQ-9 and GAD-7 scores generally showed significant differences among known groups defined by characteristics of their child with hemophilia (eg, child's hemophilia severity or treatment regimen), which may indicate that anxiety or depression in a caregiver could be associated with management of their child's disease. No significant differences were seen for caregiver age; however, the majority of caregivers (130, 87%) were in the 30-to 45-year-old group with few younger or older caregivers. 10 There are some limitations of this study that should be considered when interpreting our results. The participants of B-HERO-S were recruited through advocacy organizations, and therefore the results may be reflective of individuals who are affiliated with these groups; it is possible that individuals seeking information or assistance from advocacy organizations are more symptomatic or affected by their condition than the hemophilia population as a whole.
In contrast, PWH or caregivers of children who experience mild or no symptoms may be less likely to be engaged with advocacy groups, and may not be as willing to take an hour of time to respond to a patient/caregiver survey. B-HERO-S respondents with mild hemophilia predominantly had factor levels below 20% (75% of mild participants had factor levels of 6%-20%) and this was consistent for men and women responding as adults with hemophilia B. 10 Therefore, the reliability and validity of these PROs in asymptomatic patients with very mild hemophilia (20%-40% factor activity) may require further evaluation and different instruments. Likewise, evaluation of symptomatic carriers who were within the caregiver respondent group in B-HERO-S was limited to assessment of depression and anxiety.
Assessment of HRQoL in asymptomatic vs symptomatic carriers apart from responding as caregivers has been inconsistent and might require evaluation using other PRO instruments. Another limitation to consider is that B-HERO-S was conducted as a one-time survey, and thus lacks sensitivity to whether the PRO instrument scores may change over time. Since data was collected via an online survey, answers to all questions were self-reported, including those used to define known groups related to chronic illnesses. Considering that the study is based on a self-reported survey, it is possible that common method bias may have influenced some results.
| CON CLUS ION
In general, multiple generic and one disease-specific PRO instruments demonstrated reliability and validity in evaluating HRQoL in adults with hemophilia B and caregivers of children with hemophilia B. These results support the use of these tools to evaluate individuals with hemophilia B, and may be valuable in assessing treatmentrelated outcomes over time associated with personalized hemophilia management.
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